1-month subacute oral toxicity study of KB-944, a new calcium antagonist, in beagles.
Using male and female Beagles, we studied the subacute toxicity of diethyl 4-(benzothiazol-2-yl)benzylphosphonate (KB-944) administered orally and the following results were obtained. No dogs died during the administration period. Both male and female dogs given 200 mg/kg and those given 100 mg/kg underwent body weight decrease and inhibition of body weight increase, respectively. Enlargement of liver cells occurred in male dogs given 200 mg/kg and female dogs given 100 or 200 mg/kg. There were no further findings, even histopathologically, which showed any toxic effect of the drug. The maximum non-toxic dose of this drug was considered to be 30 mg/kg.
D000818:Animals; D052160:Benzothiazoles; D001769:Blood / Q000187:drug effects; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D001835:Body Weight / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000633:toxicity*; D004285:Dogs; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D004562:Electrocardiography; D005260:Female; D008297:Male; D009929:Organ Size / Q000187:drug effects; D013844:Thiazoles / Q000633:toxicity*; D014556:Urine / Q000032:analysis
D052160:Benzothiazoles; D002121:Calcium Channel Blockers; D013844:Thiazoles; C035950:fosfedil